Univariate and multivariate analyses (Cox models)* for OS and EFS in 2 cohorts: patients HLA-typed (n = 162) and patients who completed their assigned treatments (n = 104)
| Variable . | OS . | EFS . | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analyses . | Multivariate analyses . | Univariate analyses . | Multivariate analyses . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| 162 patients HLA typed | ||||||||
| HLA-identical sibling | ||||||||
| No† | 1 | .001 | 1 | .001 | 1 | .005 | 1 | .01 |
| Yes† | 0.50 (0.3-0.8) | .001 | 0.50 (0.3-0.8) | .001 | 0.62 (0.4-0.9) | .005 | 0.63 (0.4-0.9) | .01 |
| Male | 0.98 (0.7-1.5) | .92 | 0.99 (0.7-1.5) | .97 | 1.01 (0.7-1.4) | .97 | 0.94 (0.7-1.3) | .71 |
| Age (< 55y vs > 55y) | 1.04 (0.7-1.6) | .84 | 1.02 (0.7-1.6) | .93 | 1.23 (0.9-1.7) | .24 | 1.23 (0.9-1.7) | .25 |
| Ig-G myeloma | 0.85 (0.6-1.3) | .43 | 0.81 (0.5-1.2) | .33 | 0.68 (0.5-0.9) | .02 | 0.58 (0.4-0.8) | .004 |
| Durie & Salmon stage III | 0.97 (0.6-1.5) | .90 | 1.04 (0.7-1.6) | .87 | 1.13 (0.8-1.6) | .49 | 1.14 (0.8-1.6) | .49 |
| Disease status at first autograft | 0.83 (0.6-1.3) | .38 | 0.80 (0.5-1.2) | .30 | 0.66 (0.5-0.9) | .02 | 0.57 (0.4-0.8) | .003 |
| 104 patients completed assigned treatment | ||||||||
| High-dose melphalan autograft | 1 | .03 | 1 | .04 | 1 | .03 | 1 | 0.02 |
| Nonmyeloablative allograft | 0.55 (0.3-0.9) | .03 | 0.56 (0.3-1.0) | .04 | 0.61 (0.4-0.9) | .03 | 0.60 (0.4-0.9) | 0.02 |
| Variable . | OS . | EFS . | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analyses . | Multivariate analyses . | Univariate analyses . | Multivariate analyses . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| 162 patients HLA typed | ||||||||
| HLA-identical sibling | ||||||||
| No† | 1 | .001 | 1 | .001 | 1 | .005 | 1 | .01 |
| Yes† | 0.50 (0.3-0.8) | .001 | 0.50 (0.3-0.8) | .001 | 0.62 (0.4-0.9) | .005 | 0.63 (0.4-0.9) | .01 |
| Male | 0.98 (0.7-1.5) | .92 | 0.99 (0.7-1.5) | .97 | 1.01 (0.7-1.4) | .97 | 0.94 (0.7-1.3) | .71 |
| Age (< 55y vs > 55y) | 1.04 (0.7-1.6) | .84 | 1.02 (0.7-1.6) | .93 | 1.23 (0.9-1.7) | .24 | 1.23 (0.9-1.7) | .25 |
| Ig-G myeloma | 0.85 (0.6-1.3) | .43 | 0.81 (0.5-1.2) | .33 | 0.68 (0.5-0.9) | .02 | 0.58 (0.4-0.8) | .004 |
| Durie & Salmon stage III | 0.97 (0.6-1.5) | .90 | 1.04 (0.7-1.6) | .87 | 1.13 (0.8-1.6) | .49 | 1.14 (0.8-1.6) | .49 |
| Disease status at first autograft | 0.83 (0.6-1.3) | .38 | 0.80 (0.5-1.2) | .30 | 0.66 (0.5-0.9) | .02 | 0.57 (0.4-0.8) | .003 |
| 104 patients completed assigned treatment | ||||||||
| High-dose melphalan autograft | 1 | .03 | 1 | .04 | 1 | .03 | 1 | 0.02 |
| Nonmyeloablative allograft | 0.55 (0.3-0.9) | .03 | 0.56 (0.3-1.0) | .04 | 0.61 (0.4-0.9) | .03 | 0.60 (0.4-0.9) | 0.02 |
OS indicates overall survival; EFS, event-free survival; HR, hazard ratio; and CI, confidence interval.
In both cohorts, multivariable HRs were adjusted for sex (male vs female), age (< 55 years vs > 55), Ig-G myeloma (Ig-G vs others), Durie & Salmon stage (III vs I or II), disease status pre-first autograft (partial and complete remission vs less than a partial remission).